PARUL DEV: Open Payments
NPI 1962610634 · GAINESVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$677 in 29 payments from 13 companies in 2025. Trend: 2023 $658 · 2024 $693 · 2025 $677
Food & beverage: $677
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 6 | $158 |
| Otsuka America Pharmaceutical, Inc. | 3 | $99 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $73 |
| Alkermes, Inc. | 3 | $71 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Janssen Pharmaceuticals, Inc | 1 | $39 |
| Neurocrine BioSciences, Inc. | 2 | $38 |
| Corium, LLC | 1 | $28 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| Tris Pharma Inc | 1 | $22 |
Products named: HETLIOZ, FANAPT, CAPLYTA, REXULTI, ARISTADA, INVEGA SUSTENNA, INGREZZA, UZEDY.
Industry payments across GA — which companies pay providers there.
